A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

Key Inclusion Criteria:

   - Diagnosis of active or active/chronic ISN/RPS 2003 Class III or IV proliferative LN as
   evidenced by renal biopsy performed within 6 months. Participants may co-exhibit Class
   V disease in addition to either Class III or Class IV disease

   - Urine protein to creatinine ratio greater than or equal to (>/=) 1 on a 24-hour
   collection

   - Other inclusion criteria may apply

Key Exclusion Criteria:

   - Pregnancy or breastfeeding

   - Severe renal impairment or the need for dialysis or renal transplantation

   - Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months
   prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin,
   or voclosporin during the 2 months prior to screening or during screening

   - Significant or uncontrolled medical disease which, in the investigator's opinion,
   would preclude patient participation

   - Known active infection of any kind or recent major episode of infection

   - Intolerance or contraindication to study therapies

   - Other exclusion criteria may apply